# Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)

> **NCT01244230** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 100 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** fexofenadine/Allegra (M016455)

## Key facts

- **NCT ID:** NCT01244230
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244230, "Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01244230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*